RESUMEN
INTRODUCTION: Allogeneic hematopoietic cell transplantation (HCT) can be curative for acute myeloid leukemia (AML). Novel therapies may render patients' bone marrow hypocellularity and lead to prolonged post-therapy pancytopenia. Patients' bone marrow cellularity (BMC) at pretransplant assessment and post-treatment pancytopenia (classification CR-incomplete [CRi]) may manifest AML persistence. METHODOLOGY: We retrospectively examined the impact of BMC and ELN response (ELNr) on a single-center cohort of 337 patients who underwent allogeneic HCT for AML in CR1. RESULTS: Median follow-up was 33 months. Overall survival (OS) for the whole cohort was 55.8% at 2 years, while cumulative incidence of relapse (CIR) was 20.8%, and non-relapse mortality was 27.5%. OS and CIR were not significantly different between BMC groups; and neither was ELNr. ELNr CRi was associated with BMC aplastic and hypocellular marrow states (P < 2.6e-8). Multivariate analysis confirmed neither BMC nor attainment of ELNr CR vs CRi affected OS or relapse. Significant factors for survival included age at transplant, cytogenetic risk, development of acute Gr II-IV GvHD, and moderate-severe chronic GvHD, while cytogenetic risk and chronic GvHD affected relapse. CONCLUSION: Neither ELNr status nor pretransplant BMC influenced relapse post-HCT or OS. Hypocellularity and CRi are not negative prognostic factors for post-HCT outcomes of AML.
Asunto(s)
Células de la Médula Ósea/patología , Enfermedad Injerto contra Huésped/patología , Trasplante de Células Madre Hematopoyéticas/métodos , Leucemia Mieloide Aguda/terapia , Pancitopenia/patología , Trasplante Homólogo/métodos , Adolescente , Adulto , Factores de Edad , Anciano , Células de la Médula Ósea/inmunología , Femenino , Enfermedad Injerto contra Huésped/etiología , Enfermedad Injerto contra Huésped/inmunología , Enfermedad Injerto contra Huésped/mortalidad , Humanos , Leucemia Mieloide Aguda/inmunología , Leucemia Mieloide Aguda/mortalidad , Leucemia Mieloide Aguda/patología , Masculino , Persona de Mediana Edad , Análisis Multivariante , Agonistas Mieloablativos/administración & dosificación , Agonistas Mieloablativos/efectos adversos , Pancitopenia/etiología , Pancitopenia/inmunología , Pancitopenia/mortalidad , Recurrencia , Estudios Retrospectivos , Análisis de Supervivencia , Acondicionamiento PretrasplanteRESUMEN
The aim of the study was to determine peculiarities of the distribution, diagnosis and development of immune cytopenias in patients with chronic lymphocytic leukemia (CLL) and to evaluate the efficacy of the different therapeutic approaches. MATERIALS AND METHODS: Treatment response and survival of 83 patients with CLL complicated by immune cytopenia (IC) were analyzed. Treatment schedules in 58 medicated patients included corticosteroids; chemotherapy (COP, CHOP regimens), immunotherapy (rituximab alone), immunochemotherapy (rituximab-containing regimens - R-COP, R-CHOP). Twenty-five patients underwent splenectomy. RESULTS: The use of corticosteroids, as the first line of treatment, resulted in short-term remission in most patients. Chemotherapy was effective in a half of CLL patients, but duration of the remission did not exceed 32 months in CLL associated with autoimmune hemolytic anemia and immune thrombocytopenia. After rituximab monotherapy (10 patients) the stable remission was reached in 60% of the patients with median relapse-free survival of 40 months. Rituximab containing chemotherapy (22 patients) caused the long-term remission in 72% of the patients with median relapse-free survival of 76 months. Splenectomy performed in 25 patients with CLL complicated by IC was effective in 70% of the patients. The outcome of splenectomy depends on IC entity. The best response was registered in associated immune thrombocytopenia (median overall survival 118 months), the worst - in Fisher - Evans syndrome (15 months). CONCLUSIONS: The treatment of patients with CLL complicated by ICs should be individualized. For CLL patients without significant enlargement of lymph nodes and spleen, low lymphocytosis, associated with autoimmune hemolytic anemia or immune thrombocytopenia, the monotherapy with rituximab is optimal. In case of occurrence of autoimmune hemolytic anemia, immune thrombocytopenia or Fisher - Evans syndrome in CLL patients with enlargement of lymph nodes, spleen, significant lymphocytosis, the use of R-COP or R-CHOP schemes, 4-6 courses, is the most effective. Splenectomy is indicated in patients with massive splenomegaly, the resistance to medication, recurrent relapses after adequate therapy.
Asunto(s)
Autoinmunidad , Leucemia Linfocítica Crónica de Células B/complicaciones , Pancitopenia/diagnóstico , Pancitopenia/etiología , Pancitopenia/terapia , Adulto , Anciano , Biomarcadores , Terapia Combinada , Manejo de la Enfermedad , Susceptibilidad a Enfermedades , Femenino , Humanos , Inmunohistoquímica , Inmunofenotipificación , Leucemia Linfocítica Crónica de Células B/mortalidad , Masculino , Persona de Mediana Edad , Pancitopenia/mortalidad , Pronóstico , Modelos de Riesgos Proporcionales , Resultado del TratamientoRESUMEN
We analyzed the mutational profile of idiopathic cytopenia of undetermined significance (ICUS) compared with that of myelodysplastic syndrome (MDS). Targeted sequencing of 88 genes associated with myeloid malignancies was performed using samples of bone marrow mononuclear cells from ICUS and MDS patients. Forty patients with ICUS and 128 patients with MDS were included in this study. The median mutational burden was 0.7 mutation/person in the ICUS group and 2.2 mutation/person in the MDS group. ASXL1 (seven patients) was the most frequently mutated gene. ASXL1 was an independent significant prognostic factor for event-free survival (EFS) and overall survival (OS) (hazard ratio (HR) = 10.07 and 30.63, p = .004 and .003, respectively). The ASXL1 mutation which is frequently detected in elderly patients is a molecular predictor for pancytopenia and survival in patients with ICUS. A larger prospective study is needed to validate the role of this genetic mutation in an ICUS prognosis.
Asunto(s)
Biomarcadores , Síndromes Mielodisplásicos/complicaciones , Síndromes Mielodisplásicos/genética , Pancitopenia/diagnóstico , Pancitopenia/etiología , Proteínas Represoras/genética , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Biopsia , Médula Ósea/patología , Aberraciones Cromosómicas , Femenino , Humanos , Cariotipificación , Masculino , Persona de Mediana Edad , Mutación , Síndromes Mielodisplásicos/mortalidad , Pancitopenia/mortalidad , Pronóstico , Análisis de Secuencia de ADN , Análisis de Supervivencia , Adulto JovenRESUMEN
A novel vaccine against bovine viral diarrhea (BVD) induced pathogenic antibody production in 5-10% of BVD-vaccinated cows. Transfer of these antibodies via colostrum caused Bovine neonatal pancytopenia (BNP) in calves, with a lethality rate of 90%. The exact immunological mechanisms behind the onset of BNP are not fully understood to date. To gain further insight into these mechanisms, we analyzed the immune proteome from alloreactive antibody producers (BNP cows) and non-responders. After in vitro stimulation of peripheral blood derived lymphocytes (PBL), we detected distinctly deviant expression levels of several master regulators of immune responses in BNP cells, pointing to a changed immune phenotype with severe dysregulation of immune response in BNP cows. Interestingly, we also found this response pattern in 22% of non-BVD-vaccinated cows, indicating a genetic predisposition of this immune deviant (ID) phenotype in cattle. We additionally analyzed the functional correlation of the ID phenotype with 10 health parameters and 6 diseases in a retrospective study over 38 months. The significantly increased prevalence of mastitis among ID cows emphasizes the clinical relevance of this deviant immune response and its potential impact on the ability to fight infections.
Asunto(s)
Animales Recién Nacidos/inmunología , Diarrea Mucosa Bovina Viral/prevención & control , Mastitis/inmunología , Pancitopenia/inmunología , Vacunas Virales/efectos adversos , Crianza de Animales Domésticos , Animales , Animales Recién Nacidos/sangre , Antígenos Virales/inmunología , Diarrea Mucosa Bovina Viral/virología , Bovinos , Calostro/inmunología , Calostro/metabolismo , Virus de la Diarrea Viral Bovina/inmunología , Femenino , Incidencia , Isoanticuerpos/inmunología , Isoanticuerpos/metabolismo , Isoantígenos/inmunología , Linfocitos , Mastitis/epidemiología , Pancitopenia/mortalidad , Pancitopenia/veterinaria , Fenotipo , Embarazo , Estudios Retrospectivos , Vacunación/efectos adversos , Vacunas Virales/administración & dosificaciónRESUMEN
AIM: Methotrexate (MTX) has the potential to cause serious adverse reactions and even mortality. We analyzed the predisposing factors and outcome in patients with MTX-induced pancytopenia admitted into our unit from 1996 to 2015. METHODS: Patients were identified by departmental database search. Pancytopenia was defined as white blood cell count (WBC) < 3500 cells/mm3 , hemoglobin (Hb) < 11 g/dL and platelet count < 150 000 cells/mm3 . Severe pancytopenia was defined as WBC < 2000 cells/mm3 , Hb < 10 g/dL and platelet count < 50 000 cells/mm3 . RESULTS: Forty-six patients were included in the study (female = 35). Twenty-four had been under the care of either primary care physicians or orthopedic surgeons and presented to us with pancytopenia. Sixteen patients had severe pancytopenia. Disease distribution was as follows: rheumatoid arthritis 33, psoriasis eight, systemic sclerosis two and others three. The median dose of MTX was 10 mg/week and median duration of treatment was 11 months. The median cumulative dose was 750 mg. Symptoms at presentation included: oral mucositis (n = 37); fever (n = 24); diarrhea (n = 12), bleeding gums (n = 5) and purpura (n = 3). The potential risk factors were: hypoalbuminemia (n = 23), renal insufficiency (n = 14), dosing errors (n = 13) and non-supplementation of folates (n = 7). Thirteen patients died. WBC at admission was found to determine survival (P < 0.05). CONCLUSION: In patients on MTX, oral mucositis and fever can herald pancytopenia. MTX-induced pancytopenia is associated with high mortality. WBC at admission is the most important prognostic factor. There is need for increased awareness among physicians to minimize prescribing errors. A national guideline on monitoring of patients on MTX is desirable.
Asunto(s)
Antirreumáticos/efectos adversos , Artritis Reumatoide/tratamiento farmacológico , Metotrexato/efectos adversos , Pancitopenia/inducido químicamente , Psoriasis/tratamiento farmacológico , Esclerodermia Sistémica/tratamiento farmacológico , Adulto , Artritis Reumatoide/diagnóstico , Artritis Reumatoide/mortalidad , Biomarcadores/sangre , Bases de Datos Factuales , Femenino , Hemoglobinas/metabolismo , Humanos , Recuento de Leucocitos , Masculino , Persona de Mediana Edad , Pancitopenia/sangre , Pancitopenia/diagnóstico , Pancitopenia/mortalidad , Recuento de Plaquetas , Psoriasis/diagnóstico , Factores de Riesgo , Esclerodermia Sistémica/diagnósticoRESUMEN
BRCA1 is a well-known DNA repair pathway component and a tissue-specific tumor suppressor. However, its role in hematopoiesis is uncertain. Here, we report that a cohort of patients heterozygous for BRCA1 mutations experienced more hematopoietic toxicity from chemotherapy than those with BRCA2 mutations. To test whether this reflects a requirement for BRCA1 in hematopoiesis, we generated mice with Brca1 mutations in hematopoietic cells. Mice homozygous for a null Brca1 mutation in the embryonic hematopoietic system (Vav1-iCre;Brca1F22-24/F22-24) developed hematopoietic defects in early adulthood that included reduced hematopoietic stem cells (HSCs). Although mice homozygous for a huBRCA1 knockin allele (Brca1BRCA1/BRCA1) were normal, mice with a mutant huBRCA1/5382insC allele and a null allele (Mx1-Cre;Brca1F22-24/5382insC) had severe hematopoietic defects marked by a complete loss of hematopoietic stem and progenitor cells. Our data show that Brca1 is necessary for HSC maintenance and normal hematopoiesis and that distinct mutations lead to different degrees of hematopoietic dysfunction.
Asunto(s)
Proteína BRCA1/genética , Células Madre Hematopoyéticas/metabolismo , Adulto , Anciano , Alelos , Animales , Proteína BRCA1/deficiencia , Proteína BRCA1/metabolismo , Proteína BRCA2/genética , Proteína BRCA2/metabolismo , Recuento de Células Sanguíneas , Diferenciación Celular/efectos de los fármacos , Línea Celular , Ciclofosfamida/farmacología , Femenino , Técnicas de Sustitución del Gen , Hematopoyesis/efectos de los fármacos , Células Madre Hematopoyéticas/citología , Hemoglobinas/análisis , Humanos , Linfocitos/citología , Linfocitos/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Persona de Mediana Edad , Mutagénesis , Pancitopenia/etiología , Pancitopenia/mortalidad , Pancitopenia/patología , Adulto JovenRESUMEN
Melioidosis, an infectious disease with high mortality, caused by Burkholderia pseudomallei, is endemic in southeast Asia and northern Australia. In Indonesia, autochthonous cases have been rarely reported, with most cases being sporadic and occurring in travelers. Herein, we report a fatal case of neurological melioidosis in a traveler from Indonesia presenting with septic shock.
Asunto(s)
Melioidosis/complicaciones , Melioidosis/mortalidad , Pancitopenia/etiología , Pancitopenia/mortalidad , Adulto , Burkholderia pseudomallei/patogenicidad , Humanos , Indonesia , Masculino , Choque Séptico/etiología , Choque Séptico/mortalidadRESUMEN
OBJECTIVE: To compare the hematological parameters and clinical symptoms between Bovine Neonatal Pancytopenia (BNP) diseased calves dying before and after 14 days of life. MATERIAL AND METHODS: Clinical observations included 47 calves from dams which underwent a 3-year vaccination program with the inactivated PregSure® BVD vaccine. In 25 of these 47 BNP affected calves blood examinations were performed and in 22 dead calves diagnosis was mainly based on post-mortem findings. RESULTS: Cutaneous bleeding was the predominant clinical manifestation in 32 from 47 calves (68.1%). Seven from 47 calves (14.9%) developed cutaneous bleeding as the only symptom and 17 from 47 calves (36.2%) demonstrated these alterations in combination with hemorrhagic lesions of the oral mucosa. In 66.0% (31/47) of calves petechiae of the oral mucosa were seen and petechiation without any other BNP related symptoms occurred in eight from 47 calves (17.0%). The hematological analysis revealed thrombocytopenia in all 25 cases (n = 23: PLT < 60 x 109/l, n = 2: PLT 139-164 x 109/l). Nineteen from 25 calves (76.0%) developed thrombocytopenia and leukocytopenia (WBC < 3.5 x 109/l). In nine of them a decrease of erythrocyte count (RBC < 4.5 x 109/l), hemoglobin concentration (Hb < 8 g/dl) and packed cell volume (PCV < 24%) was measured. Three BNP affected calves without clinical symptoms were identified by hematological examination. The average life time of BNP affected calves was 14.7 ± 6.2 days. Clinical findings, especially multifocal cutaneous hemorrhages were more frequently recognized in calves living longer than 14 days. CONCLUSION AND CLINICAL RELEVANCE: At the time of falling ill with BNP, older calves displayed more numerous symptoms, especially bleeding in the skin. Thrombocytopenia and erythropenia occur as well as a decreased hemoglobin concentration and a low PCV. The time between outbreak of symptoms and death of calves which fell ill later, did not differ from the survival time of BNP calves, which displayed symptoms at a younger age. A decrease of thrombocytes was the cardinal laboratory finding.
Asunto(s)
Enfermedades de los Bovinos/sangre , Pancitopenia/veterinaria , Animales , Recuento de Células Sanguíneas , Bovinos , Enfermedades de los Bovinos/diagnóstico , Enfermedades de los Bovinos/mortalidad , Enfermedades de los Bovinos/patología , Femenino , Hemorragia/sangre , Hemorragia/patología , Hemorragia/veterinaria , Pancitopenia/diagnóstico , Pancitopenia/mortalidad , Pancitopenia/patología , EmbarazoRESUMEN
In major ABO-mismatched allogeneic hematopoietic stem cell transplantation (HSCT) persistence of antidonor isohemagglutinins leads to pure red cell aplasia (PRCA). To investigate severe pancytopenia noted in a previous study of PRCA, we analyzed all major ABO-mismatched HSCT between January 2003 and December 2012. Of 83 PRCA patients, 13 (16%) had severe pancytopenia. Severe pancytopenia was defined as an absolute neutrophil count (ANC) < 1.5 K/µL or requiring granulocyte colony-stimulating factor, platelets < 50 K/µL or transfusion dependent, and PRCA with RBC transfusion dependence at post-transplant day 90. In 6 patients (46%) severe pancytopenia resolved after PRCA resolution. Two patients (15%) received a second transplant because of persistent pancytopenia/secondary graft failure, 1 (8%) died from secondary graft failure despite a stem cell boost, 1 (8%) did not recover his platelet counts despite RBC/ANC recovery, and 3 patients (23%) died from disease relapse. We found that severe pancytopenia is frequently associated with PRCA in 16% of major ABO-incompatible HSCT with a higher incidence in males and pancytopenia resolved with resolution of PRCA in 46% of patients.
Asunto(s)
Sistema del Grupo Sanguíneo ABO , Trasplante de Células Madre Hematopoyéticas , Pancitopenia , Aplasia Pura de Células Rojas , Índice de Severidad de la Enfermedad , Adulto , Anciano , Aloinjertos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pancitopenia/sangre , Pancitopenia/etiología , Pancitopenia/mortalidad , Aplasia Pura de Células Rojas/sangre , Aplasia Pura de Células Rojas/mortalidad , Aplasia Pura de Células Rojas/terapia , Estudios Retrospectivos , Factores de TiempoRESUMEN
We retrospectively assessed the clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria (PNH) according to severity of cytopenia. A total of 282 patients with hematological parameters assessed at the time of diagnosis of PNH were included. There were 24 patients with PNH/severe aplastic anemia (SAA) (at least two of the three criteria; hemoglobin ≤8 g/dL; absolute neutrophil count (ANC) <0.5 × 10(9)/L; platelet count <20 × 10(9)/L), 96 patients with PNH/aplastic anemia (AA) (at least two of the three criteria; hemoglobin ≤10 g/dL; ANC 0.5-1.5 × 10(9)/L; platelet count 20-100 × 10(9)/L), and 162 classic PNH patients. Compared with the classic PNH subgroup, the PNH/SAA subgroup had a significantly lower median granulocyte PNH clone size (26.7 vs. 51.0 %, P = 0.021) and lower incidence of lactate dehydrogenase ≥1.5 times the upper limit of normal (52.9 vs. 80.0 %, P = 0.049). The incidence of thromboembolism was similar in both subgroups. Overall survival was significantly lower in the PNH/SAA subgroup than in the classic PNH subgroup (P = 0.033). Our findings suggest that identification of patients with PNH/SAA at the time of diagnosis is important because of different clinical manifestations and poorer outcome compared with patients with classic PNH (clinicaltrials.gov identifier: #NCT01224483).
Asunto(s)
Hemoglobinuria Paroxística/clasificación , Hemoglobinuria Paroxística/diagnóstico , Pancitopenia/clasificación , Pancitopenia/diagnóstico , Sistema de Registros , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Femenino , Hemoglobinuria Paroxística/mortalidad , Humanos , Masculino , Persona de Mediana Edad , Pancitopenia/mortalidad , República de Corea/epidemiología , Estudios Retrospectivos , Tasa de Supervivencia/tendencias , Adulto JovenRESUMEN
Pancytopenia is seen in late HIV infection; it is associated with medical complications and with decreased survival. We determined the prevalence of pancytopenia at baseline in a cohort of HIV-positive Hispanics living in Puerto Rico, and compared their socio-demographic, immunological and clinical characteristics. A total of 1202 patients enrolled between 2000 and 2010 were included. They were grouped according to pancytopenia status, defined by having: platelets <150,000 µL, white cell count <4000 µL, and hemoglobin <12 g/dL (women) or <13 g/dL (men). Differences were evaluated using Student's t-test, Chi-square test and Kaplan-Meier method. The prevalence of pancytopenia was 8.7%. Patients with pancytopenia had lower BMI and lower CD4 count, as well as higher HIV viral load and higher proportions of unemployment, clinical AIDS and antiretroviral treatment (ART) use (p < 0.05). One-year mortality rate was significantly higher in patients with pancytopenia (18.1% vs. 5.1%, p < 0.001). When stratifying for ART this association persisted for patients who did not receive ART (41.4% vs. 5.2%, p < 0.001), but it was not seen in patients who received treatment (9.2% vs. 5.6%, p = 0.196). Pancytopenia was associated with elements of advanced stages of HIV. ART could reduce the mortality of HIV-patients with pancytopenia to levels comparable to patients without the disorders.
Asunto(s)
Infecciones por VIH/complicaciones , Hispánicos o Latinos , Pancitopenia/etnología , Síndrome de Inmunodeficiencia Adquirida/virología , Adulto , Anciano , Fármacos Anti-VIH/uso terapéutico , Recuento de Linfocito CD4 , Femenino , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/etnología , Infecciones por VIH/mortalidad , Humanos , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Pancitopenia/tratamiento farmacológico , Pancitopenia/mortalidad , Pancitopenia/virología , Prevalencia , Puerto Rico/epidemiología , Carga ViralRESUMEN
OBJECTIVE: To study the clinical features of patients with refractory cytopenia of childhood (RCC). METHODS: The clinical data of 1 420 children (0-14 years old) with an initial diagnosis of non-severe aplastic anemia between January 1990 and June 2013 were retrospectively analyzed. Bone marrow cell morphology and histopathology were re-evaluated, and the patients were re-classified using the criteria proposed in the 2008 edition of the World Health Organization classification of RCC in hematopoietic and lymphoid tumor tissues. The clinical outcomes were followed up every 3-6 months. RESULTS: Among all the 1 420 cases, 152 (10.7%) were reassessed as RCC. Patients with RCC had a lower level of hemoglobin and a higher percentage of fetal hemoglobin than those with non-severe aplastic anemia. Of the patients with RCC, 21.5% showed abnormal karyotypes at diagnosis. The median follow-up period for all patients was 36 months (ranging from 1 to 283 months). The rates of complete response, partial response, and no response to cyclosporine and androgen treatment in RCC patients were 19.0%, 26.7%, and 54.3%, respectively. The 5- and 10-year prospective overall survival rates of RCC patients were 87.9% and 72.4%, respectively. The 5- and 10-year prospective clonal evolution rates were 15.3% and 20.0%, respectively. The 2-year prospective incidence of newly diagnosed karyotype abnormality after the initial diagnosis was 3.6%. The 5- and 10-year prospective leukemia transformation rates were 10.0% and 20.0%, respectively. CONCLUSIONS: RCC shows clinical features similar to adult myelodysplastic syndrome. Children with RCC have a poor prognosis, an increased risk of transformation to leukemia, and a low response rate to cyclosporine treatment.
Asunto(s)
Síndromes Mielodisplásicos/tratamiento farmacológico , Pancitopenia/tratamiento farmacológico , Adolescente , Niño , Preescolar , Evolución Clonal , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Síndromes Mielodisplásicos/mortalidad , Pancitopenia/mortalidad , Pronóstico , Estudios RetrospectivosAsunto(s)
Subunidad beta del Factor de Unión al Sitio Principal/genética , Regulación del Desarrollo de la Expresión Génica , Hematopoyesis/genética , Pancitopenia/genética , Células Madre/metabolismo , Animales , Antígenos CD/genética , Antígenos CD/metabolismo , Plaquetas/metabolismo , Plaquetas/patología , Diferenciación Celular , Linaje de la Célula/genética , Proliferación Celular , Subunidad beta del Factor de Unión al Sitio Principal/deficiencia , Hemoglobinas/metabolismo , Humanos , Leucocitos/metabolismo , Leucocitos/patología , Ratones , Ratones Noqueados , Pancitopenia/metabolismo , Pancitopenia/mortalidad , Pancitopenia/patología , Recuento de Plaquetas , Células Madre/patología , Análisis de SupervivenciaRESUMEN
UNLABELLED: Idiopathic portal hypertension (IPH) is a rare cause of intrahepatic portal hypertension. Data on natural history and prognosis of IPH are limited. We sought to describe the complications and long-tem outcome of IPH by retrospectively studying 69 biopsy-proven cases of IPH. Mean duration of follow-up was 6.7 ± 4.6 years. All patients had evidence of portal hypertension (PH) at diagnosis, and 42% were symptomatic. Variceal bleeding (VB) was the most common manifestation. In those without bleeding at diagnosis, 74% had varices at first endoscopy. In those with large varices, the 1-year probability of first bleeding despite primary prophylaxis was 9%. The 1-year probability of rebleeding was 22%. Ascites and hepatic encephalopathy was documented in 26% and 7% of patients, respectively, at least once during the clinical course. The 1-year probability of developing portal vein thrombosis (PVT) was 9%, and 53% of patients receiving anticoagulation achieved recanalization. Human immunodeficiency virus (HIV) infection and VB at diagnosis were the independent predictors of PVT. Seven patients died (6 as a result of an IPH-related cause) and 2 were transplanted. Probability of liver transplantation-free survival was 82% at 10 years. Presence of a severe associated disorder and ascites as a presenting symptom were associated with poor survival. CONCLUSION: Variceal bleeding is a major complication of IPH. Using, in IPH patients, the same management approach for PH as in cirrhosis is safe and maintains a low incidence of first bleeding and rebleeding in IPH patients. PVT is a frequent complication, particularly in those with HIV infection. Despite several complications, overall survival of patients with IPH is considerably good.
Asunto(s)
Hipertensión Portal/complicaciones , Hipertensión Portal/fisiopatología , Cirrosis Hepática/complicaciones , Cirrosis Hepática/fisiopatología , Pancitopenia/complicaciones , Pancitopenia/fisiopatología , Esplenomegalia/complicaciones , Esplenomegalia/fisiopatología , Adulto , Endoscopía del Sistema Digestivo , Femenino , Estudios de Seguimiento , Hemorragia Gastrointestinal/etiología , Hemorragia Gastrointestinal/terapia , Humanos , Hipertensión Portal/mortalidad , Circulación Hepática , Cirrosis Hepática/mortalidad , Masculino , Persona de Mediana Edad , Pancitopenia/mortalidad , España/epidemiología , Esplenomegalia/mortalidad , Trombosis/etiología , Resultado del Tratamiento , Adulto Joven , Hipertensión Portal Idiopática no CirróticaRESUMEN
The International Prognostic Scoring System (IPSS) is an important standard for assessing prognosis of primary untreated adult patients with myelodysplastic syndromes (MDS). To refine the IPSS, MDS patient databases from international institutions were coalesced to assemble a much larger combined database (Revised-IPSS [IPSS-R], n = 7012, IPSS, n = 816) for analysis. Multiple statistically weighted clinical features were used to generate a prognostic categorization model. Bone marrow cytogenetics, marrow blast percentage, and cytopenias remained the basis of the new system. Novel components of the current analysis included: 5 rather than 3 cytogenetic prognostic subgroups with specific and new classifications of a number of less common cytogenetic subsets, splitting the low marrow blast percentage value, and depth of cytopenias. This model defined 5 rather than the 4 major prognostic categories that are present in the IPSS. Patient age, performance status, serum ferritin, and lactate dehydrogenase were significant additive features for survival but not for acute myeloid leukemia transformation. This system comprehensively integrated the numerous known clinical features into a method analyzing MDS patient prognosis more precisely than the initial IPSS. As such, this IPSS-R should prove beneficial for predicting the clinical outcomes of untreated MDS patients and aiding design and analysis of clinical trials in this disease.
Asunto(s)
Médula Ósea/patología , Análisis Citogenético , Síndromes Mielodisplásicos/clasificación , Síndromes Mielodisplásicos/mortalidad , Pancitopenia/diagnóstico , Pancitopenia/mortalidad , Adulto , Anciano , Anciano de 80 o más Años , Aberraciones Cromosómicas , Femenino , Humanos , Agencias Internacionales , Cariotipificación , Masculino , Persona de Mediana Edad , Síndromes Mielodisplásicos/patología , Pronóstico , Medición de Riesgo , Factores de Riesgo , Tasa de SupervivenciaRESUMEN
OBJECTIVE: To describe the complications and adverse effects of postoperative radiotherapy in patients with Fanconi anemia (FA). DESIGN: Cohort study. SETTING: Patients with FA treated at community and tertiary care hospitals throughout the United States. PATIENTS: The study included patients with FA who were enrolled in the International FA Registry (IFAR) and who developed head and neck squamous cell carcinoma and received postoperative radiotherapy. MAIN OUTCOME MEASURES: Demographics of patients with FA and adverse effects and dosages of radiotherapy. RESULTS: Twelve patients with FA (7 men and 5 women) were identified. They developed cancers at a mean age of 35.5 years (age range, 20-48 years). The sites of primary cancer were the oral cavity (n = 8), larynx (n = 2), pharynx (n = 1), and unknown (n = 1). The median radiation dose was 5590 cGy (range, 2500-7020 cGy). The most common adverse effects were mucositis (n = 9), dysphagia (n = 8), and pancytopenia (n = 6). Other complications included esophageal stenosis, laryngeal edema, and wound breakdown. Radiotherapy could not be completed in 5 cases. Overall, 8 patients died, 4 during the course of radiotherapy. The postoperative disease-free survival time ranged from 0 to 55 months. CONCLUSIONS: Patients with FA have a high rate of complications from radiotherapy. Common adverse effects, particularly mucositis, are especially prevalent and difficult to manage in this population. Pancytopenia is common and may lead to further complications, particularly bleeding and infection. Overall survival is poor. Further study of the response to radiotherapy in patients with FA should be attempted to establish appropriate dosages to balance treating disease while limiting adverse effects.
Asunto(s)
Carcinoma de Células Escamosas/radioterapia , Carcinoma de Células Escamosas/cirugía , Anemia de Fanconi/complicaciones , Neoplasias de Oído, Nariz y Garganta/radioterapia , Neoplasias de Oído, Nariz y Garganta/cirugía , Adulto , Carcinoma de Células Escamosas/mortalidad , Estudios de Cohortes , Terapia Combinada , Supervivencia sin Enfermedad , Anemia de Fanconi/mortalidad , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Neoplasias de Oído, Nariz y Garganta/mortalidad , Pancitopenia/complicaciones , Pancitopenia/mortalidad , Complicaciones Posoperatorias/etiología , Traumatismos por Radiación/etiología , Dosificación Radioterapéutica , Radioterapia Adyuvante , Adulto JovenRESUMEN
Profiles of blood cell counts were evaluated for 15 calves from three different farms. These calves showed petechia in the mucous membranes and in the skin and prolonged secondary bleeding after puncture. The clinical course of the disease could be observed in eleven calves. With exception of one case, the blood cell counts indicated a severe anaemia, leukocytopenia and thrombocytopenia. Out of these 15 calves, six calves survived and the other nine calves died or had to be euthanized due to the severity of the disease. Necropsy of these nine calves revealed petechia in the skin, subcutis, muscles, in inner organs and all serous membranes. Pathohistological examination showed a depletion of the bone marrow and lymphatic tissue in eight calves. These findings confirmed the diagnosis of bovine neonatal pancytopenia (BNP) for eight of these nine calves. Bluetongue virus serotype 8 was tested negatively using PCR. Bovine virus diarrhoea virus (BVDV) was negatively tested using immunofluorescence and cell culture and salmonella species were negatively tested in seven dissected calves. A cluster of toxins was negatively tested in one of the dissected calves. All 15 calves had high antibody titres for BVDV. The BVDV-antibody titres from twelve dams with affected calves were positive in six cases and not detectable in the other six cases. In three of the six dams with not detectable BVDV-antibody titres, calves were fed with colostrum of a further dam with high BVDV-antibody titres. In the further three dams without detectable BVDV-antibody titres, we could not ascertain which colostrum has been fed to the calves. BVDV-specific antigen could not be detected in any of the samples from the calves and dams tested. Using the activity of the gamma-glutamyl-transferase, we assumed a sufficient supply with colostrum for the examined calves.The cause for the occurrence of these BNP cases was due to bone marrow depletion.The reason for the bone marrow depletion remained unclear. However, it was obvious that the BNP described here is highly likely caused by colostrum from cows with positive BVDV-antibody titres.
Asunto(s)
Enfermedades de los Bovinos/diagnóstico , Enfermedades de los Bovinos/etiología , Pancitopenia/veterinaria , Animales , Animales Recién Nacidos , Anticuerpos Antivirales/sangre , Recuento de Células Sanguíneas , Diarrea Mucosa Bovina Viral/complicaciones , Diarrea Mucosa Bovina Viral/diagnóstico , Diarrea Mucosa Bovina Viral/transmisión , Bovinos , Enfermedades de los Bovinos/mortalidad , Enfermedades de los Bovinos/patología , Calostro/virología , Virus de la Diarrea Viral Bovina/fisiología , Femenino , Alemania , Hematócrito , Masculino , Pancitopenia/etiología , Pancitopenia/mortalidad , Pancitopenia/patología , Factores de TiempoRESUMEN
We report our experience on rituximab-cyclophosphamide-dexamethasone (RCD) combination therapy for the treatment of autoimmune disorders in 48 patients with chronic lymphocytic leukemia (CLL). The diagnosis of autoimmune disease (AID) was autoimmune hemolytic anemia (AIHA) in 26 (54%), autoimmune thrombocytopenic purpura (AITP) in nine (18.8%), Evans syndrome in eight (16.7%), and pure red cell anemia (PRCA) in five patients (10.5%). CLL was considered progressive in 40% of subjects upon AID diagnosis. Overall, an 89.5% response rate was obtained with this combination, irrespective of the AID type. Relapse occurred in 19 patients (39.6%). The median duration of autoimmunity was 24 months, but the duration of response of autoimmunity (DR-AI) was higher for patients presenting with: (1) AID early during the CLL course (<3 years), or (2) both and pure red cell aplasia (PRCA) in five patients (10.5%) and AIHA.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Enfermedades Autoinmunes/complicaciones , Enfermedades Autoinmunes/tratamiento farmacológico , Leucemia Linfocítica Crónica de Células B/complicaciones , Pancitopenia/complicaciones , Pancitopenia/tratamiento farmacológico , Adulto , Anciano , Anciano de 80 o más Años , Anticuerpos Monoclonales de Origen Murino/administración & dosificación , Enfermedades Autoinmunes/mortalidad , Ciclofosfamida/administración & dosificación , Dexametasona/administración & dosificación , Supervivencia sin Enfermedad , Femenino , Humanos , Leucemia Linfocítica Crónica de Células B/mortalidad , Masculino , Persona de Mediana Edad , Pancitopenia/inmunología , Pancitopenia/mortalidad , Estudios Retrospectivos , Rituximab , Resultado del TratamientoRESUMEN
BACKGROUND: The objective was to demonstrate feasibility and therapeutic efficacy of routine clinical use of the bendamustine/rituximab combination in lymphoproliferative diseases. PATIENTS AND METHODS: Data were collected retrospectively from 71 patients treated with bendamustine/rituximab combination in Tyrol/Austria. Toxicities, therapeutic response, and survival outcome in the various lymphoma entities were analyzed. RESULTS: There was considerable hematotoxicity, with neutropenia and thrombocytopenia of grade 3 or 4 in 33% and 18%, respectively. Interestingly, severe infection of grade 3 or 4 was observed in a remarkable percentage of patients with aggressive lymphoma and CLL (21% and 28%, respectively) but not in indolent lymphoma (p = 0.027). Overall, the therapeutic efficacy of bendamustine/rituximab was encouraging. In CLL, an overall response rate (ORR) of 65% was achieved. Notably, in the seven previously untreated CLL patients, ORR was 86%. The therapy was effective across all FISH-cytogenetic subgroups, except for the five patients harboring 17p deletion with unfavorable prognosis (PFS 2.7 months, OS 9.3 months). In indolent lymphoma (n = 25), the bendamustine-rituximab combination induced a remarkable therapeutic effect (ORR 96%, median PFS and OS not reached). In aggressive lymphoma (n = 20), ORR was 50%; in International Prognostic Index high-risk patients (4 or 5 risk factors, n = 10), ORR was only 20%, significantly inferior than in low/intermediate risk patients (ORR 70%; p = 0.025). CONCLUSIONS: In the routine setting aside clinical studies, bendamustine/rituximab therapy resulted in marked clinical responses, especially in CLL and indolent lymphoma. In aggressive lymphoma, the combination of bendamustine and rituximab was effective in favorable risk patients.
Asunto(s)
Anticuerpos Monoclonales de Origen Murino/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Trastornos Linfoproliferativos/tratamiento farmacológico , Compuestos de Mostaza Nitrogenada/administración & dosificación , Adulto , Anciano , Anciano de 80 o más Años , Anticuerpos Monoclonales de Origen Murino/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Austria , Clorhidrato de Bendamustina , Niño , Estudios de Cohortes , Relación Dosis-Respuesta a Droga , Quimioterapia Combinada , Estudios de Factibilidad , Femenino , Humanos , Lactante , Estimación de Kaplan-Meier , Leucemia Linfocítica Crónica de Células B/tratamiento farmacológico , Leucemia Linfocítica Crónica de Células B/mortalidad , Linfoma/tratamiento farmacológico , Linfoma/mortalidad , Trastornos Linfoproliferativos/mortalidad , Masculino , Persona de Mediana Edad , Compuestos de Mostaza Nitrogenada/efectos adversos , Infecciones Oportunistas/inducido químicamente , Infecciones Oportunistas/mortalidad , Pancitopenia/inducido químicamente , Pancitopenia/mortalidad , Estudios Retrospectivos , Rituximab , Resultado del TratamientoRESUMEN
We report a case of 25-year-old woman with severe tracheobronchial necrosis caused by chlorine released from a mixture household cleaning agents. She subsequently exposed benzene while she was fixing the seats with benzene containing gum. The case was found interesting with its history, delayed diagnosis, bronchoscopic features, and fatal outcome. We presented its bronchoscopic and pathological images which has not been shown in the literature up to date.